» Articles » PMID: 8781417

Thrombopoietin Stimulates Megakaryocytopoiesis, Myelopoiesis, and Expansion of CD34+ Progenitor Cells from Single CD34+Thy-1+Lin- Primitive Progenitor Cells

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1996 Sep 1
PMID 8781417
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Thrombopoietin (TPO) or MpI ligand is known to stimulate megakaryocyte (MK) proliferation and differentiation. To identify the earliest human hematopoietic cells on which TPO acts, we cultured single CD34+Thy-1+Lin- adult bone marrow cells in the presence of TPO alone, with TPO and interleukin-3 (IL-3), or with TPO and c-kit ligand (KL) in the presence of a murine stromal cell line (Sys1). Two distinct growth morphologies were observed: expansion of up to 200 blast cells with subsequent differentiation to large refractile CD41b+ MKs within 3 weeks or expansion to 200-10,000 blast cells, up to 25% of which expressed CD34. The latter blast cell expansions occurred over a 3- to 6-week period without obvious MK differentiation. Morphological staining, analysis of surface marker expression, and colony formation analysis revealed that these populations consisted predominantly of cells committed to the myelomonocytic lineage. The addition of IL-3 to TPO-containing cultures increased the extent of proliferation of single cells, whereas addition of KL increased the percentage of CD34+ cells among the expanding cell populations. Production of multiple colony-forming unit-MK from single CD34+Thy-1+Lin- cells in the presence of TPO was also demonstrated. In limiting dilution assays of CD34+Lin- cells, TPO was found to increase the size and frequency of cobblestone areas at 4 weeks in stromal cultures in the presence of leukemia inhibitory factor and IL-6. In stroma-free cultures, TPO activated a quiescent CD34+Lin-Rhodamine 123lo subset of primitive hematopoietic progenitor cells into cycle, without loss of CD34 expression. These data demonstrate that TPO acts directly on and supports division of cells more primitive than those committed to the MK lineage.

Citing Articles

Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients.

Hsu T, Tsai C, Liu C, Yeh C, Lin F, Hsiao L Transfus Med Hemother. 2023; 50(1):39-50.

PMID: 36818774 PMC: 9912005. DOI: 10.1159/000525565.


Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.

Zhang B, Li L, Ho Y, Li M, Marcucci G, Tong W J Clin Invest. 2016; 126(3):975-91.

PMID: 26878174 PMC: 4767357. DOI: 10.1172/JCI79196.


Requirement of TPO/c-mpl for IL-17A-induced granulopoiesis and megakaryopoiesis.

Tan W, Liu B, Barsoum A, Huang W, Kolls J, Schwarzenberger P J Leukoc Biol. 2013; 94(6):1303-8.

PMID: 23990627 PMC: 4051276. DOI: 10.1189/jlb.1212639.


Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.

Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y Stem Cell Res. 2012; 9(2):77-86.

PMID: 22683680 PMC: 3412938. DOI: 10.1016/j.scr.2012.05.001.


Ex vivo expansion of cord blood.

Kelly S, Sola C, de Lima M, Shpall E Bone Marrow Transplant. 2009; 44(10):673-81.

PMID: 19802023 PMC: 4157906. DOI: 10.1038/bmt.2009.284.